Mestag Therapeutics

Mestag Therapeutics » Signaling a new era in immunotherapy

Business Model
B2B
Total Funding
$85.0M
Last Round
$40.0M Growth EquityMar 2026
Rounds
3

About

Mestag Therapeutics develops first-in-class antibody therapies that target fibroblast immunology for cancer and inflammatory diseases. The company is advancing treatments that harness activated fibroblasts to restore proper immune function for patients who do not benefit from current options. Its portfolio includes MST-0312, a bispecific antibody designed to generate a specialized immune response against cancer cells by forming tertiary lymphoid structures in solid tumors and progressing toward a first clinical trial, plus the M402 agonist-antibody program aimed at inflammatory diseases such as rheumatoid arthritis, IBD, and lupus.

Summary

Mestag Therapeutics is a Biotech company. It has raised $85.0M in total across 3 rounds, most recently a $40.0M Growth Equity round in Mar 2026. Investors include Forbion Capital Partners, SV Health Investors and Johnson & Johnson Innovation.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Growth EquityGrowth EquityMar 2026
$40.0M

Sign up to see all 3 rounds

Seed through Growth Equity — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Mestag Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/mestag-therapeutics"><img src="https://indexed.vc/api/badge/company/mestag-therapeutics" alt="Mestag Therapeutics on Indexed.vc" width="260" height="76" /></a>